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Abstract: Despite a large number of neuroimaging studies in schizophrenia reporting subtle brain abnormalities, we do 
not know to what extent such abnormalities reflect the effects of antipsychotic treatment on brain structure. We therefore 
systematically reviewed cross-sectional and follow-up structural brain imaging studies of patients with schizophrenia 
treated with antipsychotics. 30 magnetic resonance imaging (MRI) studies were identified, 24 of them being longitudinal 
and six cross-sectional structural imaging studies. In patients with schizophrenia treated with antipsychotics, reduced gray 
matter volume was described, particularly in the frontal and temporal lobes. Structural neuroimaging studies indicate that 
treatment with typical as well as atypical antipsychotics may affect regional gray matter (GM) volume. In particular, typi-
cal antipsychotics led to increased gray matter volume of the basal ganglia, while atypical antipsychotics reversed this ef-
fect after switching. Atypical antipsychotics, however, seem to have no effect on basal ganglia structure. 
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1. INTRODUCTION 
 Schizophrenia is a severe psychiatric disorder that affects 
about 1% of the population and is one of the top ten causes 
of disability worldwide [1]. Despite decades of research the 
neurobiological basis of schizophrenia is still largely un-
known [2]. However, modern neuroimaging techniques have 
enabled us to examine the brains of patients with schizo-
phrenia in vivo. A large body of neuroimaging studies have 
reported that as the illness proceeds, patients rapidly lose 
cerebral gray matter (GM), particularly in the frontal, tempo-
ral and limbic lobes [3, 4]. The treatment of schizophrenia 
involves the use of antipsychotic drugs (typical antipsycho- 
tics, such as haloperidol), which act as antagonists at central 
dopamine D2 receptors [5, 6], although some of them have 
additional effects on other receptors [7]. A new generation of 
antipsychotic drugs, the atypical antipsychotics (for example 
quetiapine, olanzapine, risperidone and clozapine), with a 
lower affinity and occupancy for the dopaminergic receptors, 
but an additional occupancy for the serotoninergic 5-HT2A 
and other receptors [8] have become available. Antipsychot-
ics are effective in reducing the severity of positive psy-
chotic symptoms but have limited impact on negative symp-
toms, cognitive impairment and produce a range of side ef-
fects including extra-pyramidal symptoms, prolactin eleva-
tion, sedation and cardio-metabolic effects [7]. Compared to 
typical antipsychotics, atypical antipsychotics induce less 
extra-pyramidal adverse effects and more metabolic adverse  
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effects [7] but the underlying neurobiological mechanisms 
are still unclear. 
 One way to better understand these mechanisms is to use 
neuroimaging to investigate structural brain changes associ-
ated with a specific class of antipsychotic drugs. Neuroimag-
ing is a potentially powerful tool to explore the impact of 
antipsychotic medication on brain structure in schizophrenia. 
Neuroimaging studies indicate that schizophrenia is associ-
ated with neuroanatomical abnormalities, with robust evi-
dence of reduced GM volume in a number of cerebral re-
gions [9, 10]. In particular these studies demonstrated 
volumetric reductions in the whole brain, in the prefrontal 
cortex and in the superior and medial temporal lobes [4, 11-
14]. These neuroimaging findings are also supported by 
post-mortem studies [15, 16]. 
 Studies of schizophrenia and other psychiatric disorders 
have suggested that the ability of antipsychotic medication to 
induce anatomical and molecular changes in the brain may 
be relevant for its antipsychotic properties in addition to their 
action on neurotransmission [17-21]. However, despite con-
siderable research, a major concern for neuroimaging studies 
of patients with schizophrenia is the potential confound of 
antipsychotic medication. Thus, it remains unclear to what 
extent structural changes are due to the ongoing illness pro- 
cess and to what extent to medication and how different anti- 
psychotic medications affect neuroimaging measures. The 
aim of this article is to systematically review neuroimaging 
studies addressing the impact of antipsychotic medication on 
brain structure. In addition, we examine the different effects 
of typical and atypical antipsychotic medication.  
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2. METHODS 
Selection Procedures 
Search Strategy 
 Electronic searches were performed using PUBMED 
database on antipsychotic medication and neuroimaging. 
Since our main focus was to examine potential different 
medication effects of typical and atypical antipsychotics on 
neuroimaging measures, we included all existing structural 
neuroimaging studies of adult and childhood-onset schizo-
phrenia published until November 2008, without any lan-
guage restriction. Patients met diagnostic criteria for schizo-
phrenia or schizophreniform or schizoaffective disorder ac-
cording to Diagnostic and Statistical Manual of Mental Dis-
orders DSM-III-R or DSM-IV criteria. The search terms 
were: schizophrenia, antipsychotic medication, typical antip-
sychotic, atypical antipsychotic, conventional antipsychotic, 
basal ganglia, ventricular enlargement, caudate, cortical 
gray, white matter (WM), morphometry, brain imaging, neu-
roimaging, magnetic resonance imaging, and MRI.  
Selection Criteria 
 First, studies that investigated brain structure and differ-
ences between groups of patients treated with typical or atypi- 
cal antipsychotics were included. We hand-searched all the 
publications in order to find longitudinal and cross-sectional 
neuroimaging studies considering the effects of antipsychotic 
medication as well as the references of all manuscripts for 
further relevant publications. To qualify for inclusion in this 
review the studies must have: (a) been an original publica-
tion in a peer-reviewed journal (b) studying schizophrenic 
patients using neuroimaging techniques according to anti- 
psychotic medication (c) considering the differences in 
medication either among various antipsychotic medications 
or over the time among various groups of patients.  
 According to their clinical stage, patients with schizo-
phrenia were considered as patients with a first episode (de-
fined as first hospitalization [22], less than five years` total 
duration of disease [23]), recent onset (first hospitalization 
within the last 5 years [22]), chronic patients (disease dura-
tion greater than five years [24], disease duration more than 
ten years [23]), or therapy resistant chronic patients (chronic 
and refractory to conventional treatment [25]). We used the 
term antipsychotic-naïve for those patients who have never 
used any antipsychotic medication and ‘antipsychotic-free’ 
for patients free of antipsychotic medication for at least two 
months before admission [26]. 
Recorded Variables 
 One approach for systematic reviews is to survey the 
literature and then provide an informed interpretation of the 
main findings. However, with this approach the review's 
summarising process may be opaque to the reader, who can-
not assess the validity of the conclusions without reading the 
original papers. In the present review we have tried to help 
the readers to form their own opinion by presenting a num-
ber of key quantitative measures from the studies reviewed 
in informative tables. Two of the authors extracted the data 
independently (SB and RS). The recorded variables for arti-
cles used in the review were: type of medication, mean dose 
of the used drugs, chlorpromazine equivalents, regional 
volumetric brain differences, type of study design (longitu-
dinal/cross-sectional) and imaging analysis method (region-
of-interest, voxel-based morphometry) and the demographic 
characteristics of patients groups.  
3. RESULTS 
 In recent years a large number of neuroimaging studies 
have been conducted to evaluate the variations and longitu-
dinal changes in brain structure in various groups of patients, 
often reporting contradictory results. 30 studies published 
between 1996 and 2008 met the inclusion criteria and were 
reviewed, 24 of them being longitudinal and six cross-
sectional structural imaging studies. Table 1 contains an 
overview of all reviewed studies for better orientation. 
Structural Neuroimaging Studies  
 We reviewed structural MRI studies evaluating GM vol-
ume differences between patients and healthy controls 
(cross-sectional) as well as progressive changes (longitudi-
nal) in whole and regional brain volumes and compared 
these between groups of patients according to their antipsy-
chotic treatment. 
Cross-Sectional MRI Studies 
 In total, six cross-sectional MRI studies were reviewed. 
Two cross-sectional studies compared patients treated with 
typical antipsychotics only to healthy controls [22, 24] and 
four studies compared patients treated with different antipsy-
chotics [3, 23, 27].  
 The results of Kopelman et al. suggest that patients 
treated with typical antipsychotics have a thicker cortical 
depth of the left anterior cingulate gyrus without displaying 
any difference in surface area compared to healthy controls 
[24]. In another study increasing exposure to typical antipsy-
chotics correlated with a larger insular volume, but the dif-
ferences between patients and healthy controls were not sig-
nificant [22]. 
 Brain structural changes associated with the use of typi-
cal or atypical antipsychotics in first-episode psychosis pa-
tients are mostly qualitative, because they appear as signifi-
cant in each group compared only to the drug-free group. 
Treatment with typical antipsychotics was associated with an 
enlargement of the basal ganglia and size reductions in in-
sula, extending into inferior frontal and superior temporal 
gyrus, in lobulus paracentralis, anterior cingulate gyrus and 
precuneus [27]. However, treatment with atypical antipsy-
chotics was associated solely with an enlargement of the 
thalami [27]. Pituitary volume was 30 % larger in the first-
episode patients receiving typical antipsychotics and 17% 
larger in patients receiving atypical antipsychotics compared 
to healthy controls [28]. Higher doses of a typical antipsy-
chotic were associated with larger caudate, putamen and 
thalamus volumes, whereas a higher dose of an atypical an-
tipsychotic only with larger thalamic volume [3]. First-
episode schizophrenic patients treated with atypical antipsy-
chotics had larger hippocampal volumes than those treated 
with typical antipsychotics [23]. The specifics of each of 
these cross-sectional MRI studies have been included in  
Table 2. 
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Table 1. Overview of Reviewed Studies 
 Population  
  Patients 
Medication  Medication  
Study  
(Reference)  
C Typical Atypical AF/AN 
Specification of  
Study Design 
Typicals, n of Subjects,  
Mean Dose 
CPZ E 
mg/d  
Atypicals, n of Subjects,  
Mean Dose 
CPZ E  
mg/d  
Chakos et al. - 
2004 [42] 
10 8 FE    21 AN 
standardized neuroleptic 
regimens fewer than 12 
weeks or none (enter of the 
study) 
up to 3 diff. neuroleptics  
(n of subjects n/a)  
400 - 900 
up to 3 diff. neuroleptics  
(n of subjects n/a) 
400 - 900 
Chakos et al. - 
2005 [23] 
26 
22 (17 FE, 5 
ChP) 
32 (15 FE, 
17 ChP) 
_ 
FE: 17 haloperidol, 15 
atypicals = 12 olanzapine, 3 
risperidone, 1 clozap-
ine+molindone, 1 unknown; 
Ch P: 5 typicals = 3 halop-
eridol, 1 trifluoroperzine, 1 
thiothixene,17 atypicals = 6 
olanzapine, 8 clozapine, 3 
risperidone 
17 haloperidol, 1 clozap-
ine+molindone, Ch P: 5 
typicals = 3 haloperidol, 1 
trifluoroperzine, 1 thiothix-
ene 
n/a 
12 olanzapine, 3 risperidone, 1 
clozapine+molindone; 6 
olanzapine, 8 clozapine, 3 
risperidone 
n/a 
Christensen  
et al. - 2004 [30] 
8 16 FE   _ 
AF baseline Ā  4 week 
continued hospitalization: 4 
mg risperidone, 7 mg 
haloperidol, 120 mg zipra-
sidone 
haloperidol (7 mg) 350 
risperidone (4 mg), ziprasi-
done (120 mg) 
200; 200 
Chua et al. - 
2008 [31] 
_ 15 FE 5 FE 25 AN _ 
13 haloperidol, 1 trifluor-
perazine, 1 sulpirid 
318 5 amisulpirid  318 
Corson et al. - 
1999 [46] 
_ 
13 FE 
(5 typ + 
atyp.) 
10 FE  
(4 type + 
typ.) 
_ 
time of intake: 4 AN, 14 
typ., 5 typ.+ atyp.; 
haloperidol, trifluoperazine, 
thiothixene, fluphenazine, 
thioridazine, perphenazine, 
chlorpromazine (n of 
subjects n/a) 
n/a 
clozapine, risperidone, olan-
zapine (n of subjects n/a) 
n/a 
 Dazzan et al. - 
2005 [27] 
_ 32 FE 30 FE 
13 AN 
+ 9 AF 
cross-sectional non-
randomized, VBM 
chlorpromazine, sulpiride, 
haloperidol, thioridazine, 
droperidol, trifluoperazine, 
zuclopenthixol (n of sub-
jects n/a) 
 
269.5+245 
21 olanzapine (14mg), 5 
risperidone (4mg), 2 quetiap-
ine (400mg), 1 sertindole 
(16mg), 1 amisulpiride 
(400mg) 
280; 200; 
533; 
sertindole 
n/a; 400 
Frazier et al. - 
1996 [38] 
8 _ 8 _ 2 years  1 haloperidol (1mg/d) 50 8 clozapine (400 mg/d)  800 
Garver et al. - 
2005 [26] 
7 6 (3 FE) 13 (7 FE) _ 
scan before and after 28 
days of treatment 
6 haloperidol (7mg/d)  350 
7 risperidone (4mg/d) and 6 
ziprasidone (120mg/d); 
200 and 
200 
Girgis et al. - 
2006 [35] 
15 _ 15 AN _ 6 week follow-up _ _ 15 risperidone 2,67+1.23mg 133 
Gogtay et al. - 
2004 [37] 
38 _ 23 COS  _ 
baseline: 22 medication (17 
typ. and 5 atyp.) Ā  follow 
up 23 atyp.:during study 
most recived atyp. 
baseline 17 typ. (n of 
subjects n/a)  
_ 
baseline: 5 atyp., folow-up: 23 
atyp. (15 clozapine)  
n/a 
Gur et al. -  
1998 [3]  
128 
48 PT ChP - 
only typ. 
27 PT 
ChP typ. + 
atyp. 
21 AN _ 
48 typ. (28 haloperidol, 8 
haloperidol dekanoat, 6 
loxapine, 8 thioridazine, 3 
molindone, 12 thiothixene, 
4 fluphenazine, 4 
fluphenazine decanoat, 9 
trifluoperazine, 7 per-
phenazine, 8 chlorpromaz-
ine), 22 typ. + atyp. (15 
clozapine, 16 risperidone) 
407.1 
22 typ. + atyp. (15 clozapine, 
16 risperidone), 5 only risperi-
done 
58.2 -
3723.5; 
150-400; 
286.3 
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(Table 1) contd…. 
 Population  
  Patients 
Medication  Medication  
Study  
(Reference)  
C Typical Atypical AF/AN 
Specification of  
Study Design 
Typicals, n of Subjects,  
Mean Dose 
CPZ E 
mg/d  
Atypicals, n of Subjects,  
Mean Dose 
CPZ E  
mg/d  
Heitmiller et al.- 
2004 [43] 
14 
  
14 AN FE  only atyp. _ _ 
7 males: 2 risperidone, 1 
olanzapine later quetiapine, 3 
risperidone and/or olanzapine, 
1 risperidone olanzapine 
finally clozapine; 7 females: 2 
risperidone, 1 risperidone and 
/or quetiapine, 1 olanzapine, 3 
risperidone and/or olanzapine  
n/a 
Ho et al. -  
2003 [49]  
23 40 RO _ 33AN naturalistic study  7 typ., 11 typ. + atyp. 462.2 
20 atyp. (olanzapine, quetiap-
ine, risperidone, ziprasidone), 
15 clozapine  
462.2 
James et al. - 
2004 [39] 
16 _ 16 COS _ _ _ _ 16 atyp., 3 also clozapine  279 
Kopelman et al.- 
2005 [24] 
30 
30 (6 FE, 11 
RO, 13 
ChP) 
_ _ only males 
only typicals (n of subjects 
n/a) 
CPZ 
equvalents 
from 0.5 
to 650 
"dose-
year"  
_ _ 
Lang et al.-  
2004 [44] 
23 10 ChP 37 _ 
baseline typ. (10) or risperi-
done (13) - limited response 
switched to olanzapine, 14 
patients receiving risperi-
done - good response - 
continued 
baseline (10): loxapine, 
trifluoperazine, chlorpro-
mazine, fluphenazine, 
haloperidol switched to 
olanzapine  
360.1 
baseline: 13 risperidone 
switched to olanzapine, 14 
patients receiving risperidone - 
good response - continued 
olanzapine 
switched 
from 
typicals 
170.0 + 
switched 
from 
risperidone 
150.0; 
risperidone 
84.0 
Lieberman et al.- 
2005 [32] 
58 82 FE 82 FE _ 
double blind randomized 
week 0, 12, 24, 52, 104 
82 haloperidol (2-20mg/d)  100-1000 82 olanzapine (5-20mg/d) 100-400 
Massana et al. - 
2005 [36] 
_ _ 11 AN _ 
baseline: AN Ā  3 months 
risperidone 
_ _ 
14 risperidone, mean dose 
6.05mg/d  
302.5 
 McClure et al.- 
2006 [29] 
_ 
2 stabile 
ChP  
6 stabile 
ChP 
_ 
2 scans within 4-8 weeks 8 
ChP stable treatment  
1 thiothixene (10mg/d), 2 
perphenazine (8mg/d) 
200; 800 
1 clozapine (800mg/d), 1 
quetiapine (200mg/d) + 
risperiodne (4mg/d), 1 olan-
zapine (30mg/d), 1 olanzapine 
(5mg/d), 1 olanzapine 
(20mg/d), 1 risperiodne 
(9mg/d) + quetiapine 
(400mg/d) 
1600; 267; 
200; 
600;100; 
400; 450; 
533.3 
McClure et al.  
2008 [33] 
_ _ 10 ChP _ 
off medication 39.4 days, 
then brief period (12 weeks) 
atypicals 
_ _ 
olanzapine (10-20mg/day); 
risperidone (4-6mg/day); 
quetiapine (300-800mg/day); 
clozapine (500-1000mg/day) 
(n of subjects n/a) 
200-400; 
200-
300;400-
1067;1000-
2000 
McCormick et al. 
2005 [48] 
18 9 AN 22 AN _ _ 
5 haloperidol, 2 per-
phenazine, 1 fluphenazine, 
1 thiothixene (8 pure, 1 
mixed) 
dose years 
10 risperidone, 11 olanzapine, 
1 clozapine (15 pure, 7 mixed) 
dose years 
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(Table 1) contd…. 
 Population  
  Patients 
Medication  Medication  
Study  
(Reference)  
C Typical Atypical AF/AN 
Specification of  
Study Design 
Typicals, n of Subjects,  
Mean Dose 
CPZ E 
mg/d  
Atypicals,n of Subjects,  
Mean Dose 
CPZ E  
mg/d  
Molina et al.-
2005 [25] 
11 _ 
12 ChP 
TR 
17 AN 
AN: risperidone 5 + 2mg/d, 
ChP TR: baseline – halo- 
peridol 10 mg/d 1 month Ā  
converted to clozapine 
initial 410 + 339 mg/d, final 
260 + 211 mg/d 
_ _ 
risperidone (5 + 2mg/d), 
clozapine (260 + 211 mg/d)  
(n of subjects n/a) 
100 + 40; 
520 + 422 
Pariante et al. - 
2005 [28] 
78 33 FE 26 FE 
12 AN 
+ 6 AF 
cross-sectional non-
randomized, ROI 
3 depot, others oral n/a 
19 olanzapine, 5 risperidone, 1 
sertindole, 1 amisulprid 
n/a 
Pressler et al.- 
2005 [22] 
30 
30 (6 FE, 11 
RO, 13 
ChP) 
_ _ typ. at the time of scanning  
only typicals  
(n of subjects n/a) 
CPZ 
equvalents 
from 0.5 
to 650 
"dose-
year"  
_ _ 
Scheepers et al. - 
2001 [45] 
_ _ 26 ChP _ 
baseline scan before discon-
tinuating typ., after 24 
weeks follow-up 
baseline: 26 patients typ.  527 
follow up: 26 patients clozap-
ine (mean dose 345.57mg/d)  
691.1 
Stip et al. -  
2008 [34] 
Letter to the 
Editor 
_ 1 ChP 15 ChP _ 
baseline: haloperidol, 
risperidone, olanzapine Ā  2 
week discontinuation Ā  20 
weeks quetiapine  
1 haloperidol (10mg) 500 
9 risperidone (3.3 +1.4m0), 6 
olanzapine (21.2+6.29mg) Ā  
2 week discontinuation Ā  20 
weeks quetiapine (529mg) 
165; 424; 
705.3 
Strungas et al.- 
2003 [47] 
5 _ 
7 (3 FE, 4 
ChP) 
_ 
min 2 months of medication 
non-compliance Ā  drug-
free period of psychosis 
exacerbation Ā  4 mg 
risperiodone 
_ _ 7 risperidone 4mg 200 
Tauscher-
Wisniewski et 
al. - 2002 [41] 
_ 4 FE 9 FE 8 
baseline: 8 AN, 7 FE - mean 
lifetime antipsychotic 
exposure in chlorpromazine 
equivalents 15.1; Ā  4 
month: 4 typ. + 9 atyp. + 2 
typ and atyp. 
2 haloperidol (2mg/d), 2 
loxapine (10 mg/d) 
_ 
4 olanzapine (14.4mg/d), 2 
risperidone (2.5mg/d), 3 
clozapine (333mg/d); 2 typ+ 
atyp.: clozapine (400mg/d)  
288; 125; 
666; 800 
Tauscher-
Wisniewski  
et al. - 2005 [40] 
37 _ 10 AN _ 
subgroup of 10 patients  
2 scans at 12 weeks 
_ _ 10 quetiapine 494mg  660 
Thompson et al. 
- 2008 [2] 
_ 15 FE 21 FE   double blind treatment 15 haloperidol 5mg/d 250 21 olanzapine 10mg/d 200 
All studies are also referenced in the text. Abbreviations C = control; AN = antipsychotic-naïve; AF = antipsychotic free; PT = previously treated; FE = first episode; RO = recent 
onset; TR = treatment resistant; ChP = chronic patient; BG = basal ganglia; CPZ = chlorpromazine; CPZ E = chlorpromazine equivalent; VBM = voxel-based morphometry; ROI = 
region of interest; BT = before therapy; AT = after therapy; GM = gray matter. 
 
Longitudinal MRI Studies Using Voxel-Based Morphome-
try (VBM) 
 In total, 13 longitudinal MRI studies using VBM meth-
ods were reviewed. Two studies of patients treated with typi-
cal and atypical antipsychotics did not examine the differ-
ences between subgroups of antipsychotic medication [29, 
30]. Another four longitudinal studies searched for progres-
sive changes after treatment with either of atypical antipsy-
chotics [2, 26, 31, 32]. Seven studies evaluated the changes 
in brain structure after medication with only atypical anti- 
psychotic medication [33-39]. Three studies assessed chronic 
patients with schizophrenia [29, 33, 34], two studies focused 
on childhood-onset psychosis [38, 39], whereas the other 
studies only included patients with first-episode schizophre-
nia [2, 26, 30-32, 35-37]. The brain changes were compared 
with a healthy control group comprising healthy volunteers 
in seven studies [26, 30, 32, 35, 37-39]. 
 A study that examined the effects of medication with 
typical antipsychotics revealed GM increases in basal gan-
glia volume [32], whereas the basal ganglia volume re-
mained unchanged following treatment with atypical anti- 
psychotics [34].  
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Table 2. Cross-Sectional MRI Studies of Patients with Schizophrenia 
Population 
  Patients 
Regional differences in GM Regional differences in GM Regional Differences in GM 
Study 
(Reference) 
Medication 
C Typical Atypical 
AF/ 
AN 
Typical vs drug-free Voxels x y z 
Atypical vs 
drug-free 
Voxels x y z Typ. vs Atyp. Voxels x y z 
Chakos et 
al. - 2005 
(23) 
atyp. + typ. 26 
22 (17 
FE, 5 
ChP) 
32 (15 
FE, 17 
ChP) 
_ _ _ _ _ _ _ 
FE treated with 
atyp. higher 
hippocampal 
volume than FE 
treated with 
haloperidol - 
males treated with 
atypicals early in 
illness lose less 
hippocampal 
volume 
_ _ 
Dazzan et 
al. - 2005 
(27) 
atyp. + typ. _ 32 FE 30 FE 
13 
AN + 
9 AF 
Ā in R lenticular nucleus 563 
23.1 
-3.1 
2.6 
Ā in L and R 
thalamus 
310 
-2.9 
-25.8 
4.8 
Ȁ in L middle TG 
(BA 21) 
196 
-53 
-14.6 
-10.4 
Ȁ in 1) R insula, extending 
into inferior FG (BA 47), 
superior TG (BA 22) 
741 
37 
12.3 
-4.6 
_ _ _ _ _ _ 
Ȁ in 2) L and R paracentral 
lobule (BA 4,5), extending 
into superior and medial FG 
(BA 6, 31), CG (BA 24) 
717 
0 
-22.2 
46.7 
_ _ _ _ _ _  
deficits in 3) L precuneus 472 
-1.3 
-47.4 
49.4 
_ _ _ _ _ _ 
Gur et al. - 
1998 (3)  
typ. and 
typ. + atyp., 
atyp. 
128 
48 PT 
ChP 
- only 
typ. 
27 PT 
ChP 
typ. + 
atyp. 
21 
AN 
higher dose of typicals 
associated with higher 
caudate, putamen, thalamus 
volumes 
_ _ 
higher dose 
of atypicals 
associated 
with higher 
thalamus 
volume 
_ _ _ _ _ 
Kopelman 
et al. - 2005 
(24) 
only typ., 
only males 
30 
30 (6 
FE, 11 
RO, 13 
ChP) 
_ _ 
Ā of L ACG vs C due to Ā in 
cortical depth without any 
difference in surface area 
_ _ _ _ _ _ _ _ 
Pariante et 
al. - 2005 
(28)  
atyp. + typ. 78 33 FE 26 FE 
12 
AN + 
6 AF 
pituitary volume 30% larger 
vs controls 
_ _ 
pituitary 
volume 17% 
larger vs 
controls + 
15% larger 
by antipsy-
chotic free 
vs controls 
_ _ 
pituitary volume 
of patients 
receiving typicals 
is showing trend 
to be 11% larger 
vs other groups of 
patients (p=0.08) 
_ _ 
Pressler et 
al. - 2005 
(22) 
typ.  30 
30 (6 
FE, 11 
RO, 13 
ChP) 
_ _ 
nonsign. Ā volume of insular 
cortex in medicated vs Cs - 
increasing exposure to typ. 
(in dose-years) correlated 
with larger insular volume  
_ _ _ _ _ _ _ _ 
All studies are also referenced in the text. Abbreviations x y z = Talairach coordinates; C = control; AN = antipsychotic naïve; AF = antipsychotic free; PT = previously treated; FE = 
first episode; RO = recent onset; TR = chronic resistant; ChP = chronic patient; BG = basal ganglia; Ā = excess, increase, higher; Ȁ = decrease, deficit; R = right; L = left; TG = tempo-
ral gyrus; FG = frontal gyrus; CG = cingulate gyrus; BA = Brodmann area; typ. = typical antipsychotics; atyp. = atypical antipsychotics 
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 The study by Lieberman et al. [32] is the only controlled, 
double blind, randomized, multi-site longitudinal study. 
With a relatively large sample size of seventy-nine patients 
with first-episode schizophrenia, patients treated with halop-
eridol showed significant reductions in GM volume com-
pared to healthy controls. In contrast, olanzapine-treated 
patients did not show any significant decreases in GM vol-
ume during the follow up period. GM reduction in the halop-
eridol group was evident during the first 12 weeks in frontal 
GM and at week 52 in the temporal and parietal GM. Sig-
nificant volume increases in the caudate nucleus in the 
haloperidol group were observed at weeks 24, 52 and 104 
compared to olanzapine group [32].  
 In another study by Thompson et al. the dynamics of 
illness progression in treated patients were shown for typical 
versus atypical antipsychotic drugs [2]. The haloperidol-
treated group showed the fastest tissue loss in the frontal 
cortex during the first year of psychosis. In the olanzapine 
group the brain changes occurred more posteriorly in occipi-
tal and limbic regions. These results suggest that antipsy-
chotic medication may not be entirely protective. The volu-
metric changes related to antipsychotic medication are re-
gionally much more pronounced than it would be predicted 
from healthy controls. However, the differences between the 
medication groups were less pronounced after a 12-month 
period [2].  
 Among a small sample of patients with chronic schizo-
phrenia, relative volume increases in left hippocampal GM 
were found in patients treated with atypical, but not with 
typical antipsychotics [29]. Patients treated with typical an-
tipsychotics showed a trend towards decreasing total cere-
brospinal fluid (CSF) volume [29]. In medication-free 
chronic patients treated briefly with atypical antipsychotics 
no significant changes in GM volume were observed [33]. 
Results from another study of patients with chronic schizo-
phrenia showed greater GM density in the basal ganglia after 
20 weeks of medication with quetiapine [34]. These findings 
were contradictory to previous short-term follow up studies 
[26, 29, 33].  
 Individuals with first-episode psychosis, who received 
short-term treatment (six weeks) with risperidone, showed 
increased GM volume in the temporal cortex and decreased 
GM in frontal cortex. Risperidone-treatment was associated 
with reduced WM and was found in the corpus callosum, 
cerebellum and right anterior cingulate [35]. 
 In childhood-onset schizophrenia clozapine treated pa-
tients had larger caudate volume compared to healthy con-
trols [38]. However, after two years of clozapine treatment, 
caudate volume did not differ between baseline and follow-
up scan [38]. In adolescent-onset schizophrenia, smaller vol-
umes in the prefrontal cortex and thalamus, a larger fourth 
ventricle volume and a reduced cerebellar (i.e. vermis) vol-
ume were found in a longitudinal study with patients treated 
with atypical antipsychotics [39].  
 Relative to antipsychotic-naïve patients, patients receiv-
ing treatment (15 with typical, five with atypical antipsy-
chotics) had relatively greater GM volumes in the caudate 
and in the cingulate gyri extending to the left medial frontal 
gyrus [31] after three-four weeks of treatment. Results from 
recently decompensated antipsychotic-free schizophrenic 
patients showed no evidence, that a four-week antipsychotic 
treatment itself may cause volumetric change in cerebral 
WM volume [30]. Patients with childhood-onset schizophre-
nia treated for two years with atypical antipsychotics showed 
GM reductions in parietal and fronto-temporal cortices as 
well as reduced total GM volume [37]. The specifics of each 
of these longitudinal VBM studies have been included in 
Table 3. 
Longitudinal Studies Using a Region-of-Interest (ROI) 
Approach 
 In total, 11 longitudinal MRI studies using ROI methods 
were reviewed. Seven longitudinal studies using an ROI ap-
proach focused on basal ganglia [40-46], one on the thala-
mus [47], one on the anterior cingulate gyrus [48] and two 
studies on other cortical regions [25, 49]. Five studies evalu-
ated GM changes after treatment with atypical antipsychotic 
medication only [25, 40, 43, 45, 47], four compared typical 
versus atypical antipsychotic [41, 44, 46, 48] and two did not 
examine for the differences between these two subtypes of 
antipsychotic drugs [42, 49]. 
 No differences between baseline and follow-up in cau-
date volumes were seen in a subgroup of ten patients after 12 
weeks of quetiapine treatment [40]. After a five-year follow-
up only an age-related decline in caudate volume in patients’ 
treatment with both typical and atypical antipsychotics and 
healthy controls was found [41]. At the beginning the antip-
sychotic-naïve patients treated exclusively with atypical an-
tipsychotics showed only a negligible volume enlargement 
of the caudate after two years, but these changes may be sex-
dependent [43]. Female patients with a greater amount of 
drug exposure had fewer enlargements of caudate nuclei. In 
males the correlation was reversed [43]. Treatment with 
typical antipsychotics was associated with larger basal gan-
glia volumes and switching to olanzapine was associated 
with a reduction in basal ganglia volumes [44]. Volumes of 
putamen and globus pallidus were normalized following the 
switch to olanzapine. In the group of risperidone-treated pa-
tients, who later switched to olanzapine, no significant dif-
ferences in overall basal ganglia volume were seen [44]. 
Treatment with clozapine in schizophrenic patients previ-
ously treated with typical antipsychotics resulted in de-
creased caudate volume [45]. Volume of caudate and nucleus 
lentiformis increased after exposure to typical antipsychotics 
and decreased following exposure to atypical antipsychotics 
[46]. Caudate volumes increased in first-episode patients 
during 18-month treatment by 5.7% and decreased by 1.6% 
in healthy controls [42]. 
 Several other longitudinal studies in chronic and first 
episode treated with both typical and atypical medication 
have produced evidence for GM volume changes in different 
regions including the parietal and occipital lobes [25] and 
thalamic volume [49]. Exposure to typical antipsychotics 
was associated with an increase in anterior cingulate cortex 
(ACC) volume over time while exposure to the atypical class 
of antipsychotics was associated with a decrease in volume 
of ACC over time [48]. Progressive brain changes in patients 
with schizophrenia occur despite ongoing antipsychotic 
drug-treatment, however, no significant differences were 
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Table 3. Longitudinal MRI Studies of Patients with Schizophrenia 
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Regional Differences in GM Regional Differences in GM 
Regional Differ-
ences in GM 
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n 
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y 
 
(R
ef
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ce
) 
Medi- 
cation 
C 
Typical Atypical AF/AN 
Typical vs  
Drug-Free 
Num. of 
Voxels 
x y z 
Atypical vs  
Drug-Free 
Num. of  
Voxels 
x y z Typical vs Atypical 
C
hr
is
te
ns
en
 e
t a
l. 
– 
20
04
 [
30
] 
typ. + 
atyp 
8 16 _ 
responders of treatment (13 patients -   of SAPS) -   of WMV, 3  
drug-nonresponders – nonsign. Ā of WMV; no evidence, that antipsychotic  
treatment itself caused volumetric change in cerebral WMV 
_ _ 
_ 15 FE 5 FE 25 AN 
typ.+atyp. vs AN 
after 3-4 weeks: 
GMV excess in 1) L 
CG extending to L 
medial FC,L caudate 
nucleus (9%) (BA 0, 
BA 24) 
593 
-0.6 
21.8 
5.1 
_ _ _ _ 
C
hu
a 
et
 a
l. 
– 
20
08
 [3
1]
 
typ. + 
atyp 
_ _ _ _ 
2) R CG extending 
to R caudate nucleus 
(10%) (BA 0, BA 
24) 
93 
4.9 
21.2 
2.4 
_ _ _ _ 
Fr
az
ie
r 
et
 a
l. 
– 
 
19
96
 [
38
] 
atyp. 8 _ 8 _ _ _ _ 
baseline: caudate Ā in 
COS vs C, 2years Ȁ  
no diff. between 2 
groups, non-sign.   
putamen volume in 
COS vs C, non-sign. 
Ā of lateral  
ventricles in  
COS vs C 
_ _ _ 
G
ar
ve
r 
et
 a
l. 
– 
 
20
05
 (
26
) 
 
typ. + 
atyp 
7 6 (3 FE) 
13  
(7 FE) 
_ no effect _ _ 
Ā of cortical gray 
volume,   of CSF 
and WM volumes, no 
effects on the basal 
ganglia 
_ _ 
cerebral cortical gray 
expanded, no effects 
on the basal ganglia 
G
ir
gi
s 
et
 a
l. 
– 
20
06
 [
35
] 
atyp. 15 _ 15 AN _ _ _ _ 
between baseline and 
follow-up Ā GM: 1) 
L superior TG 
(BA39) 2) L middle 
TG (BA39) and   
GM 3) LFG, rectal 
gyrus (BA11)   WM 
4) L cerebrum, 
subjacent to FG 5) L 
corpus callosum 6) R 
cerebrum, subjacent 
to FG, 7) R corpus 
callosum 8) R AC 
 
1) -45,-59,19  
2) -57,-54,14  
3) -2,43,-26  
4) -19,22,17  
and  
-16,16,21  
5)-10,23,15  
6)23,19,18  
7)15,17,21  
8)7,28,15 
_ 
G
og
ta
y 
et
 a
l. 
– 
 
20
04
 [
37
] 
atyp. 38 _ 23 _ _ _ _ _ _ _ 
 longitudinally less  
P, F, T, total GMV  
V
B
M
 / 
w
ho
le
 b
ra
in
  
Ja
m
es
 e
t a
l. 
– 
 
20
04
 [
39
] 
atyp.  16 _ 16 COS _ _ _ _ 
patients (all medicated) had   mean volume in 
the prefrontal cortex (p<0.001) and thalamus 
(p=0.04) vs C; larger volumes of the fourth 
ventricle (p=0.05); longitudinally only evidence 
of progression in posterior inferior vermis 
volume amonge males  
_ 
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) 
Medi- 
cation 
C 
Typical Atypical AF/AN 
Typical vs  
Drug-Free 
Num. of 
Voxels 
x y z 
Atypical vs  
Drug-Free 
Num. of  
Voxels 
x y z Typical vs Atypical 
L
ie
be
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t a
l. 
– 
 
20
05
 [
32
] 
typ. + 
atyp 
58 79FE 82 FE _ 
haloperidol group -   
of WBGM (frontal, 
temporal, parietal) 
over time, most 
during the first 12 
weeks, Ā in lateral 
ventricle and caudate 
_ _ 
olanzapine group – 
retained WBGM 
_ _ 
caudate volumes Ā in 
haloperidol group vs 
olanzapine, magnitude 
of differences  
between groups was 
constant over time, 
but significance was 
lost 
M
as
sa
na
 e
t a
l. 
– 
 
20
05
 [
36
] 
atyp. _ _ 11 AN _ _ _ _ 
Ā in GM volume L 
and R caudate and L 
accumbens  
_ _ _ 
M
cC
lu
re
 e
t a
l. 
– 
 
20
06
 [
29
] 
typ. + 
atyp 
_ 2 ChP  6 ChP _ _ _ _ _ _ _ 
Ā in left hippocampal 
volume in atypic vs 
typ; trend towards   
total CSF volume in 
typ. 
M
cC
lu
re
 e
t a
l. 
– 
20
08
 [3
3]
 
atyp. _ _ 10 ChP _ _ _ _ 
no longit. change in 
R or L caudate, 
GMV, no effect of 
treatment status in F 
or T GMV, in 
WMV, in CSF 
volume in 3rd , 4th or 
lateral ventricles and 
in cortical sulci 
_ _ _ 
St
ip
 e
t a
l. 
– 
20
08
 [
34
] 
atyp. _ 1 15 ChP _ 
Ā GMd in BG before 
treatment with 
quetiapine:  
1) L caudate  
2) R caudate nucleus 
3) R putamen  
4) L putamen 
1) 4551  
2) 506 
and 638 
3) 20  
4) 64 
1)-14,20,6 
2)18,2,19 
and 
12,17,0  
3) 34,2,2  
4) 31,0,5 
Ā GMd in BG after 
treatment with 
quetiapine:  
1) L pallidum  
2) R putamen 
1) 1402  
2) 530  
and 124 
1) -22,-6,0  
2) 31,-22,4 
and 27,14,12 
_ 
 
T
ho
m
ps
on
 e
t a
l. 
– 
20
08
 [2
] 
typ. + 
atyp 
_ 15 FE 21 FE _ 
Trajectory of GM deficits:lateral parietal-
temporal (3 month) Ȁ  dorsolateral, medial 
frontal and prefrontal (6 months)Ȁ  most of 
the FC (1 year). Medial wall: 1. posterior CC 
Ȁ  anteriorly Ȁ  limbic cortex (6 months) Ȁ  
F and preF C (12 months); 2. posteriorly Ȁ  
occipital C. FC = greatest deficits – intense 
in 6 and 12 months 
changes more posteriorly – occipital and limbic 
regions – changes are much higher than would 
be predicted to occur normally 
typical-treated vs 
atypical-treated: 
greater GM deficits in 
medial and superior C 
(3 and 6 months) Ȁ  
only frontal cortex (12 
months) – not signifi-
cant after stringent 
multiple comparisons 
correction 
ROI 
C
ha
ko
s 
et
 a
l. 
– 
20
04
 [4
2]
 
typ. + 
atyp 
10 8 FE  21 AN 
caudate volumes 
increased in FE 
during 18-month 
treatment by 5,7% 
(greater by patients 
before medicated or 
younger) and de-
creased by HC 1.6% 
_ _ _ _ _ _ 
 
2544    Current Pharmaceutical Design, 2009, Vol. 15, No. 22 Smieskova et al. 
(Table 3) contd…. 
Population 
Patients 
Regional Differences in GM Regional Differences in GM 
Regional Differences 
in GM 
Sp
ec
if
ic
at
io
n 
St
ud
y 
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Num. of 
Voxels 
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Drug-Free 
Num. of  
Voxels 
x y z Typical vs Atypical 
C
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n 
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 a
l. 
– 
 
19
99
 [
46
] 
typ. + 
atyp 
_ 
13 FE 
(5 typ + 
atyp.) 
10 FE 
(4 atyp + 
typ.) 
_ 
typ.: Ā volume of 
caudate and lentiform 
nucleus 
_ _ 
atyp.:   volume of 
caudate and lentiform 
nucleus 
_ _ _ 
H
ei
tm
ill
er
 e
t a
l.-
 2
00
4 
[4
3]
 
atyp. 14 _ 
14 AN 
FE 
_ _ _ _ 
negligible Ā in volume 
of the caudate over 2 
years; females – the 
greater amount of drug 
exposure, the less 
enlargement , males – 
opposite – the greater 
the enlargement of 
caudate 
_ _ _ 
H
o 
et
 a
l. 
– 
20
03
 [
49
] 
typ. + 
atyp 
23 73 (33 AN, 40 RO) _ 
no significant effects from 4 treatment (typ.; atyp.; typ.+ atyp.; clozapine) measures on any 
ROIs – progressive volumetric brain changes despite antipsychotic treatment 
_ 
L
an
g 
et
 a
l. 
– 
20
04
 [
44
] 
 
typ. + 
atyp 
23 10 ChP 
37 (13 
switched 
from 
risperi-
odne, 14 
contin-
ued) 
_ 
baseline: typ. – BG 
greater (putamen by 
7%, globus pallidus 
20.7%) vs contols Ȁ  
switch to olanzapine: 
putamen volume   by 
9.8% + globus pallidus 
by 10.7% - did not 
differ from controls 
_ _ 
risperidone-treated 
switched Ȁ  olanzapine: 
no significant differ-
ences in overall BG 
_ _ 
switch to olanzapine: 
putamen volume   by 
9.8% + globus pal-
lidus by 10.7% Ȁ  did 
not differ from 
controls 
M
cC
or
m
ic
k 
et
 a
l. 
– 
20
05
 [
48
] 
typ. + 
atyp 
18 9 AN 22 AN _ 
increased typical 
exposure Ȁ  increased 
ACC over time 
_ _ 
increased atypical 
exposure Ȁ  decreased 
ACC over time 
_ _ 
the mean change in 
ACC volume – very 
small with large 
standard deviations 
M
ol
in
a 
et
 a
l. 
– 
 
20
05
 [
25
] 
atyp. 11 _ 
12 ChP 
TR 
17 AN 
baseline: ChP TR typ., 
than atyp. 
_ _ 
AN baseline: Ā in O GM + P GM vs C,   in total + O WM vs C; longi-
tudinally: the greater the initial deficit in total and P GM, the greater the 
increase in GM + the greater the initial excess total WM and its change 
in total and O WM, the greater the longitudinal decreases; ChP TR : Ā 
in total, F GM, P and O GM vs C +   in total, F, P, O WM vs C; longi-
tudinally: the greater the baseline volume excess of WM,  
the greater the   in total, F, P and O WM 
Sc
he
ep
er
s 
et
 a
l. 
– 
 
20
01
 [
45
] 
 atyp. _ _ 
26 (typ. 
before) 
_ _ _ _ _ _ _ 
clozapine   in CNV 
after typ. treatment; 
no difference in CNV 
changes between 
responders and non-
responders, no 
changes in total brain 
volume  
  
St
ru
ng
as
 e
t a
l. 
– 
 
20
03
 [
47
] 
 
atyp. 5 _ 
7 (3 FE, 
4 ChP) 
_ _ _ _ 
drug-free period: 
patients – trend smaller 
thalamic volumes 
(p<0.06); 4 weeks of 
treatment: volumetric 
expansion of L and R 
thalamus  
_ _ _ 
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C 
_ _ _ 
 
T
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r-
W
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i  
et
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l. 
- 
20
05
 [
40
] 
atyp. 37 _ 10 AN _ _ _ _ 
no difference 
between baseline 
and endpoint in 
CNV 
_ _ _ 
All studies are also referenced in the text. Abbreviations x,y,z = Talairach coordinates (MNI coordinates uncounted by www.bioimagesuite.org/Mni2Tal/index.html); C = control; AN 
= antipsychotic naïve; AF = antipsychotic free; PT = previously treated; FE = first episode; RO = recent onset; TR = chronic resistant; ChP = chronic patient; BG = basal ganglia; Ā = 
excess, increase, higher; Ȁ = decrease, deficit; R = right; L = left; TG = temporal gyrus; FG = frontal gyrus; CG = cingulate gyrus; BA = Brodmann area; typ. = typical antipsychotics; 
atyp. = atypical antipsychotics; GMV = gray matter volume, GMd = gray matter density; WM V= white matter volume; WBGM = whole brain gray matter; FC = frontal cortex; CC = 
cingulate cortex; ACC = anterior cingulate cortex; CSF = cerebrospinal fluid; COS = childhood onset schizophrenia; typ. = typicals; atyp. = atypicals; SAPS = Schedule for assess-
ment of positive symptoms; FGM = frontal gray matter; OGM = occipital GM; PGM = parietal GM; DLFG = dorsolateral frontal gyrus; SMA = supplementary motor area; CNV = 
caudate nuclei volume 
 
seen among the four different treatment groups (typical an-
tipsychotics, atypical antipsychotics, typical + atypical anti- 
psychotics, clozapine) [49]. The specifics of each of these 
longitudinal ROI studies have been included in Table 3. 
4. DISCUSSION 
 Structural neuroimaging studies can be used to examine 
the influence of antipsychotics on brain structure. Overall, 
structural imaging studies suggest that medication with typi-
cal antipsychotics leads to an increased volume of the basal 
ganglia, while atypical antipsychotics reduce this volume 
after switching.  
Effects of Antipsychotic Medication on Structural Neuro-
imaging Measures in Schizophrenia 
 There is a convergence of findings from structural neuro-
imaging studies described showing volumetric reductions in 
fronto-temporo-limbic regions may reflect pathophysiologic 
processes of schizophrenia [9, 12]. Studies of patients with 
schizophrenia demonstrate robust volumetric reductions in 
multiple brain regions and particularly in the prefrontal 
cortex and of the superior and medial temporal lobes and in 
the anterior cingulate [4, 11-14]. 
 While these findings are consistent and replicated, there 
are inconsistencies regarding the potential effect of antipsy-
chotic medication. Some studies found no significant effect 
of antipsychotic medication on brain structure [30, 33, 40, 
41, 49]. However, in many of these studies, the sample sizes 
were modest (< 30 subjects) resulting in type 2 errors. Other 
studies found ameliorative effects of (mostly atypical) antip-
sychotics on structural neuroimaging measures [38, 44, 50, 
51]. Generally, both typical and atypical antipsychotics  
respectively the illness process itself were associated with 
GM volume reductions in occipital and limbic regions [2].  
 In general, functional imaging studies underline findings 
from structural neuroimaging studies. They suggest that 
treatment with atypical antipsychotics has been associated 
with greater regional cortical activity compared to treatment 
with typical antipsychotic drugs, whereas the latter have 
been associated with relatively more striatal activity [52]. 
Atypical antipsychotics (substitution of risperidone for typi-
cal antipsychotic) also increased prefrontal activity (prefron-
tal cortex, supplementary motor area) during cognitive tasks 
(working memory) and reduced abnormally elevated subcor-
tical limbic activity during emotion processing so that brain 
activity resembled that observed in healthy volunteers [50]. 
These findings might reflect pathophysiologic processes that 
may be at least partly ameliorated by antipsychotic medica-
tion. Clozapine but not haloperidol treatment re-established 
normal task-activated regional cerebral blood flow (CBF) 
patterns in schizophrenia in the ACC [53]. This is consistent 
with the finding that atypical antipsychotics might have a 
greater effect on cognitive impairment in schizophrenia than 
typical [54].  
 Progressive brain changes in schizophrenia are consid-
ered controversial [55]. Although there is evidence for GM 
loss and ventricular enlargement from prospective studies of 
patients with first episode and chronic schizophrenia [49, 56-
61], the potential confounding impact of antipsychotics is 
still debatable. Most neuroimaging studies of schizophrenia 
to date have not included the examination of non-medicated 
patients, making conclusions about medication effects on 
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neuroimaging measures difficult. Investigation of subjects at 
the onset of the disease avoids potential confounders such as 
antipsychotic treatment [62-65]. A clinical high-risk status 
for psychosis (at risk mental state, ARMS) is associated with 
a set of neurofunctional abnormalities that are qualitatively 
similar to those observed in patients with the disorder [66]. 
As these findings are not attributable to chronic psychotic 
symptoms [67] and antipsychotic treatment, they may repre-
sent markers of increased vulnerability to psychotic disor-
ders. Structural MRI studies of non-medicated patients in a 
prodromal phase of psychosis or ARMS demonstrated that 
neuroanatomical abnormalities are already evident in the 
very early phase of psychosis. People at high risk of psycho-
sis show qualitatively similar volumetric abnormalities to 
patients with schizophrenia. Cortical brain abnormalities 
have been found in genetically defined high-risk populations 
such as first-degree relatives and co-twins of patients with 
schizophrenia, as well in people with ARMS [13, 68-80]. 
Previous longitudinal MRI studies in this group found that 
the subset of patients who developed psychosis showed a 
longitudinal reduction in GM in the orbito-frontal, temporal 
lobe, parietal lobe and cerebellum [79, 81, 82]. 
Mechanisms of Antipsychotic Action on Brain Structure  
 At present, the mechanism of action of antipsychotics is 
inferred from animal and in vitro studies. Structural neuro- 
imaging has contributed substantially to the understanding of 
the mechanisms of action of existing antipsychotic drugs. 
Thompson et al. [2] suggest pharmacologic mechanisms that 
go beyond symptom suppression via neuroreceptor antago-
nism. Those mechanisms might ameliorate the underlying 
pathophysiology that causes disease progression and the 
clinical deterioration that is the hallmark of the illness [2].  
 Furthermore, it has been suggested that antipsychotics 
might increase neurogenesis, however, neurogenesis seems 
contradictory to studies showing that antipsychotics are as-
sociated with volume reductions. Haloperidol treatment may 
be neurotoxic [25, 83] which may explain the cortical GM 
volume reduction. In a very recent study, Konopaske et al. 
[84] found a significant 20.5% reduction in astrocyte num-
bers and a non-significant 12.9% reduction in oligodendro-
cytes in antipsychotic-exposed macaque monkeys. Similar 
effects were seen in both haloperidol and olanzapine treated 
patients. These very intriguing findings of antipsychotic-
induced glial cell number reduction in animals, however, 
need to be replicated. In humans, treated with typical anti- 
psychotics, frontal GM volume reduction is correlated with 
the dose [3]. Medication-free subjects with an ARMS show 
fronto-temporal tissue reduction relative to healthy controls 
[79, 81, 82], suggesting that the loss process is not attribut-
able solely to medication.  
 Atypical antipsychotics reduce oxidative stress [85] and 
stimulate the synthesis of trophic molecules [85-88]. In pri-
mates, treatment with atypical antipsychotics led to prefron-
tal glial cell proliferation and cortical hypertrophy [89]. In 
rats, olanzapine stimulates glial cell division in the frontal 
cortex [85]. Thus, atypical antipsychotics may reduce dis-
turbed myelination and abnormally severe dendritic pruning 
and/or neurotoxic ablation of synapses [49, 90, 91] in pa-
tients with schizophrenia. Atypical antipsychotics may also 
induce oligodendrocyte proliferation and compensate for 
oligodendrocyte reductions [49] and intracortical myelination 
[90]. 
Methodological Issues in Studies Investigating Medica-
tion Effects by Neuroimaging 
 Some studies used VBM, a technique that allows com-
parisons of the entire brain volume at the single voxel level. 
Mostly, an ‘optimized’ VBM method [92] is used to mini-
mize the potentially confounding effects of errors in stereo-
tactic normalization was used. It is important to note that to 
identify regional differences in GM volume instead of GM 
concentration, ‘modulated’ versions of VBM, which in-
volves the multiplication of the spatially normalized GM by 
its relative volume before and after warping, were used. 
However, the use of VBM implicates problems of brain reg-
istration [93]. The size of the smoothing kernel is also rele-
vant, because it should be roughly the size of the expected 
findings. Although the exact meaning of the volumetric ab-
normalities is not entirely clear, GM reductions may reflect a 
variety of neuropathological changes, e.g. exaggerated den-
dritic or synaptic pruning [94], impaired myelination [90], 
apoptosis [95], or other neurotoxic effects of first-generation 
antipsychotic medications [96]. Furthermore, differences in 
scanning parameters and image analysis may account for 
inconsistencies in neuroimaging measures. 
 The results of this review raise ethical questions on antip-
sychotic use. If antipsychotic medication may lead – at least 
in some patients - to GM volume reduction careful benefit-
risk decisions have to be made for individual patients. Pa-
tients with schizophrenia should be very cautiously informed 
about the potential risks (and of course benefits) of antipsy-
chotic medication.  
 For future studies, we suggest to focus on, longitudinal 
designs that represent the gold standard for investigation of 
medication effects. These studies have clearly the advantage 
of powerful, within-subject designs. Small sample sizes, het-
erogeneity in the sociodemographic characteristics of the 
subjects, lack of consistency between scanning parameters 
also suggest future multi-site studies that have shown the 
potential to overcome most of these problems and to bridge 
basic neuroscience with clinical psychiatry. 
5. CONCLUSIONS 
 In patients with schizophrenia treated with antipsychot-
ics, reduced GM volume is described, particularly in frontal 
and temporal lobes. Medication with typical antipsychotics 
also leads to increased volume of the basal ganglia, while 
atypical antipsychotics reversed the effect after switching.  
 Neuroimaging studies have provided compelling evi-
dence that despite antipsychotic medication (both typical and 
atypical) there are detectable anatomical changes at the level 
of total and regional brain volumes. To date, it remains elu-
sive whether the effects of antipsychotic medication on GM 
volume are simply beneficial. It is questionable whether the 
effects we are observing are the direct effects of antipsychot-
ics or whether these measures are actually surrogates for 
third variables. It is also possible that the opposite could be 
true, that antipsychotics may attenuate the brain changes and 
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that compliance with medication could lead to less progres-
sive change than non-compliance. Unless we do not have 
more reliable studies from non-medicated patients, the po-
tential impact of the confounding effect of medication has to 
be kept in mind. So far, the investigation of patients at risk or 
with a first-episode of schizophrenia seems to be the most 
promising alternative.  
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ACC =  Anterior cingulate cortex 
ARMS =  At risk mental state 
CBF =  Cerebral blood flow 
CSF =  Cerebrospinal fluid 
DSM =  Diagnostic and statistic manual of mental  
disorders  
GM =  Gray matter 
MRI =  Magnetic resonance imaging 
ROI =  Region-of-interest 
VBM =  Voxel-based morphometry  
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